US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

3.39

+0.10003.04%

Post-market: 3.390.00000.00%18:52 EST

Volume:623.33K

Turnover:2.12M

Market Cap:233.79M

PE:-1.82

High:3.49

Open:3.35

Low:3.29

Close:3.29

52wk High:3.57

52wk Low:0.6500

Shares:68.96M

Float Shares:63.12M

Volume Ratio:0.31

T/O Rate:0.99%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8600

EPS(LYR):-2.1535

ROE:-338.75%

ROA:-60.73%

PB:39.18

PE(LYR):-1.57

Loading ...

Overview Company News Filings

Analysts Are Bullish on These Healthcare Stocks: Adaptive Biotechnologies (ADPT), Opus Genetics (IRD)

Iron Road (ASX:IRD) Might Have The Makings Of A Multi-Bagger

Simply Wall St.

Opus Genetics to Present Preliminary Results of OPGx-BEST1 Gene Therapy at Macula Society Annual Meeting

Opus Genetics Price Target Maintained With a $7.00/Share by BTIG

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Opus Genetics (IRD) and Argenx Se (ARGX)

Opus Genetics launches gene therapy clinical trial for retinitis pigmentosa

Opus Genetics Inc - Trial Funded by Abu Dhabi's Healthcare Research Fund

THOMSON REUTERS

Opus Genetics Inc - Clinical Development to Start at Cleveland Clinic Abu Dhabi in 2026

THOMSON REUTERS

Opus Genetics Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis Pigmentosa

THOMSON REUTERS

Opus Genetics Inc : Btig Initiates Coverage With Buy Rating; Target Price $7

THOMSON REUTERS

Opus Genetics initiated with a Buy at BTIG

Opus Genetics Initiated at Buy by BTIG

Opus Genetics Inc: Expects Its Existing Cash Resources Will Fund Operations Into Second Half of 2027

THOMSON REUTERS

Opus Genetics expects cash to fund operations into second half of 2027

Independent Chairman of Opus Genetics Picks Up 9.5% More Stock

Simply Wall St.

Opus Genetics Director Cam Gallagher Reports Acquisition of Common Shares

Opus Genetics Inc - on Dec 17, Viatris Files Supplemental Nda With FDA for Phentolamine - SEC Filing

THOMSON REUTERS

Opus Genetics Grants Stock Options to New Employee Under Inducement Plan

Foundation Fighting Blindness Retinal Degeneration Fund Sells Common Shares of Opus Genetics Inc

Opus Genetics CEO to Present at J.P. Morgan Healthcare Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IRD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":3.39,"timestamp":1770930000000,"preClose":3.29,"halted":0,"volume":623331,"hourTrading":{"tag":"盘后","latestPrice":3.39,"preClose":3.39,"latestTime":"18:52 EST","volume":2899,"amount":9825.23,"timestamp":1770940368077,"change":0,"changeRate":0,"amplitude":0.011799},"delay":0,"changeRate":0.030395136778115527,"floatShares":63122173,"shares":68964208,"eps":-1.86,"marketStatus":"Not Yet Opened","change":0.1,"latestTime":"02-12 16:00:00 EST","open":3.35,"high":3.49,"low":3.29,"amount":2118809.1572658,"amplitude":0.06079,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.86,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770973200000},"marketStatusCode":0,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":3.29,"preHourTrading":{"tag":"盘前","latestPrice":3.48,"preClose":3.29,"latestTime":"09:28 EST","volume":410,"amount":1374.899576,"timestamp":1770906503038,"change":0.19,"changeRate":0.057751,"amplitude":0.039514},"postHourTrading":{"tag":"盘后","latestPrice":3.39,"preClose":3.39,"latestTime":"18:52 EST","volume":2899,"amount":9825.23,"timestamp":1770940368077,"change":0,"changeRate":0,"amplitude":0.011799},"volumeRatio":0.311817,"impliedVol":1.3756,"impliedVolPercentile":0.7809},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":63122173,"roa":"-60.73%","roe":"-338.75%","lyrEps":-2.153504,"volumeRatio":0.311817,"shares":68964208,"dividePrice":0,"high":3.49,"amplitude":0.06079,"preClose":3.29,"low":3.29,"week52Low":0.65,"pbRate":"39.18","psRate":"15.98","week52High":3.57,"institutionHeld":0,"latestPrice":3.39,"eps":-1.86,"divideRate":0,"volume":623331,"delay":0,"ttmEps":-1.86,"open":3.35,"prevYearClose":2.01,"prevWeekClose":3.01,"prevMonthClose":2.31,"prevQuarterClose":2.01,"fiveDayClose":2.58,"twentyDayClose":2.17,"sixtyDayClose":1.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"IRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.14,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2025-08-13","symbol":"IRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.25,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.12},{"market":"US","date":"2025-05-15","symbol":"IRD","fiscalQuarterEnding":"2025/03","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2025-03-31","symbol":"IRD","fiscalQuarterEnding":"2024/12","expectedEps":-0.34,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"pre","actualEps":-1.27},{"market":"US","date":"2024-11-12","symbol":"IRD","fiscalQuarterEnding":"2024/09","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1818,"buy":0.8182,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8182,"analysts":11,"updateTime":1768971600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2026-02-11","current":-1.822581,"percent":0,"low":-3.528952,"twenty":-2.131298,"median":-1.321684,"eighty":-1.024632,"high":-0.560128,"avg":-1.51028,"sd":0.596483,"marketCap":240685085},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197},{"date":"2025-07-11","current":-1.139893,"twenty":-1.351342,"median":-1.160017,"eighty":-0.782117,"marketCap":66820540},{"date":"2025-07-18","current":-1.185692,"twenty":-1.346698,"median":-1.152239,"eighty":-0.783669,"marketCap":69505294},{"date":"2025-07-25","current":-1.231492,"twenty":-1.339732,"median":-1.160017,"eighty":-0.783669,"marketCap":72190048},{"date":"2025-08-01","current":-1.129716,"twenty":-1.335088,"median":-1.160248,"eighty":-0.785825,"marketCap":66223928},{"date":"2025-08-08","current":-1.10936,"twenty":-1.335088,"median":-1.151155,"eighty":-0.789762,"marketCap":65030704},{"date":"2025-08-15","current":-1.213067,"twenty":-1.335088,"median":-1.150071,"eighty":-0.791428,"marketCap":70691504},{"date":"2025-08-22","current":-1.177087,"twenty":-1.335088,"median":-1.151155,"eighty":-0.791428,"marketCap":68594722},{"date":"2025-08-29","current":-1.287434,"twenty":-1.335088,"median":-1.160248,"eighty":-0.791428,"marketCap":75025207},{"date":"2025-09-05","current":-1.384803,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"marketCap":80699383},{"date":"2025-09-12","current":-1.525447,"twenty":-1.342054,"median":-1.174821,"eighty":-0.822134,"marketCap":88895414},{"date":"2025-09-19","current":-1.611997,"twenty":-1.365273,"median":-1.182227,"eighty":-0.876364,"marketCap":93939125},{"date":"2025-09-26","current":-1.860829,"twenty":-1.384803,"median":-1.184928,"eighty":-0.929339,"marketCap":108439795},{"date":"2025-10-03","current":-1.947379,"twenty":-1.400101,"median":-1.195775,"eighty":-0.939944,"marketCap":113483507},{"date":"2025-10-10","current":-2.152936,"twenty":-1.42988,"median":-1.207384,"eighty":-0.94314,"marketCap":125462322},{"date":"2025-10-17","current":-2.174573,"twenty":-1.477844,"median":-1.207384,"eighty":-0.951343,"marketCap":126723249},{"date":"2025-10-24","current":-2.163754,"twenty":-1.521119,"median":-1.217191,"eighty":-0.957164,"marketCap":126092786},{"date":"2025-10-31","current":-2.131298,"twenty":-1.627334,"median":-1.225421,"eighty":-0.958345,"marketCap":124201394},{"date":"2025-11-07","current":-2.196211,"twenty":-1.661499,"median":-1.23256,"eighty":-0.960734,"marketCap":127984177},{"date":"2025-11-14","current":-2.001473,"twenty":-1.74585,"median":-1.242213,"eighty":-0.964942,"marketCap":116635827},{"date":"2025-11-21","current":-1.951541,"twenty":-1.828372,"median":-1.253822,"eighty":-0.975077,"marketCap":133100921},{"date":"2025-11-28","current":-2.153773,"twenty":-1.878321,"median":-1.253822,"eighty":-0.98727,"marketCap":146893763},{"date":"2025-12-05","current":-2.254889,"twenty":-1.925381,"median":-1.265432,"eighty":-0.988735,"marketCap":153790183},{"date":"2025-12-12","current":-2.467233,"twenty":-1.950709,"median":-1.277041,"eighty":-0.996674,"marketCap":168272667},{"date":"2025-12-19","current":-2.002099,"twenty":-2.002099,"median":-1.288651,"eighty":-1.007767,"marketCap":136549131},{"date":"2025-12-26","current":-2.062768,"twenty":-2.022322,"median":-1.288651,"eighty":-1.0085,"marketCap":140686984},{"date":"2026-01-02","current":-2.032433,"twenty":-2.02248,"median":-1.288651,"eighty":-1.00907,"marketCap":138618058},{"date":"2026-01-09","current":-2.022322,"twenty":-2.035652,"median":-1.288651,"eighty":-1.009619,"marketCap":137928416},{"date":"2026-01-16","current":-2.103215,"twenty":-2.062768,"median":-1.30026,"eighty":-1.016154,"marketCap":143445552},{"date":"2026-01-23","current":-2.527902,"twenty":-2.079519,"median":-1.303662,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-01-30","current":-2.527902,"twenty":-2.105793,"median":-1.31187,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-02-06","current":-2.608795,"twenty":-2.126582,"median":-1.317674,"eighty":-1.019861,"marketCap":177927656},{"date":"2026-02-11","current":-3.528952,"twenty":-2.131298,"median":-1.321684,"eighty":-1.024632,"marketCap":240685085}],"updateTime":1770936053886},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609594463","title":"Analysts Are Bullish on These Healthcare Stocks: Adaptive Biotechnologies (ADPT), Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2609594463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609594463?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:21","pubTimestamp":1770387677,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adaptive Biotechnologies (ADPT – Research Report) an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-adaptive-biotechnologies-adpt-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-adaptive-biotechnologies-adpt-opus-genetics-ird-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0029874061.USD","BK4585","BK4121","BK4588","XBI","BK4007","ADPT","LABU","LU0128526141.USD","BK4112","BK4137","BK4139","IRD"],"gpt_icon":0},{"id":"2608481198","title":"Iron Road (ASX:IRD) Might Have The Makings Of A Multi-Bagger","url":"https://stock-news.laohu8.com/highlight/detail?id=2608481198","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608481198?lang=en_us&edition=fundamental","pubTime":"2026-02-03 06:47","pubTimestamp":1770072425,"startTime":"0","endTime":"0","summary":"If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ird/iron-road-shares/news/iron-road-asxird-might-have-the-makings-of-a-multi-bagger","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ird/iron-road-shares/news/iron-road-asxird-might-have-the-makings-of-a-multi-bagger","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IRD","IRD.AU","BK4007","BK7129","BK4139","EBIT"],"gpt_icon":0},{"id":"2608861851","title":"Opus Genetics to Present Preliminary Results of OPGx-BEST1 Gene Therapy at Macula Society Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2608861851","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608861851?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:00","pubTimestamp":1770037215,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. will participate in several upcoming medical and industry conferences in February 2026. The company’s leadership will join discussions at the Collaborative Community on Ophthalmic Innovation  and the Asia-Pacific Academy of Ophthalmology Congress , both taking place in Hong Kong from February 3-8, 2026. Additionally, Opus Genetics’ Chief Technology Officer, Chris Ernst, will speak at the Advanced Therapies Week Conference in San Diego, CA, on February 11, 2026. The company will also present preliminary results from a clinical study at the Macula Society Annual Meeting in San Diego, CA, on February 27, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to genera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL2wVhzg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU0314104364.USD","IRD","BK4585","SG9999014039.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","BK4139","BK4588","SG9999014013.SGD","BK4007","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014021.USD","BK4112","LU2095319765.USD","NDAQ"],"gpt_icon":0},{"id":"2606792917","title":"Opus Genetics Price Target Maintained With a $7.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2606792917","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606792917?lang=en_us&edition=fundamental","pubTime":"2026-01-28 18:17","pubTimestamp":1769595420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 05:17 ET (10:17 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2606733627","title":"Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Opus Genetics (IRD) and Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2606733627","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606733627?lang=en_us&edition=fundamental","pubTime":"2026-01-27 23:00","pubTimestamp":1769526036,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Intellia Therapeutics (NTLA – Research Report), Opus Genetics (IR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-intellia-therapeutics-ntla-opus-genetics-ird-and-argenx-se-argx-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-intellia-therapeutics-ntla-opus-genetics-ird-and-argenx-se-argx-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","BK4505","LU0889565916.HKD","IE00BFTCPJ56.SGD","HCSG","LU2324357040.USD","BK4007","LU1861559042.SGD","XBI","XLV","IE0034235188.USD","BK4137","IE00B4R5TH58.HKD","LU0029874061.USD","NTLA","BK4581","LU0320765992.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","BK4588","BK4535","IE0009355771.USD","LU1861558580.USD","IE0002141913.USD","BK4139","LU1983260115.SGD","LABU","IE00B2B36J28.USD","BK4585","ARGX","IRD","LU0128526141.USD","BK4556"],"gpt_icon":0},{"id":"2606781856","title":"Opus Genetics launches gene therapy clinical trial for retinitis pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2606781856","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606781856?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:16","pubTimestamp":1769516171,"startTime":"0","endTime":"0","summary":"Opus Genetics (IRD) announced the launch and funding of its clinical trial evaluating a gene therapy for MERTK-related retinitis pigmentosa. The st...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-launches-gene-therapy-clinical-trial-for-retinitis-pigmentosa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-launches-gene-therapy-clinical-trial-for-retinitis-pigmentosa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2606789886","title":"Opus Genetics Inc - Trial Funded by Abu Dhabi's Healthcare Research Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2606789886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606789886?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:00","pubTimestamp":1769515201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUAL7JFC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2606786002","title":"Opus Genetics Inc - Clinical Development to Start at Cleveland Clinic Abu Dhabi in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2606786002","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606786002?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:00","pubTimestamp":1769515201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUAL7JFC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2606700786","title":"Opus Genetics Launches Gene Therapy Clinical Trial for Mertk-Related Retinitis Pigmentosa","url":"https://stock-news.laohu8.com/highlight/detail?id=2606700786","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606700786?lang=en_us&edition=fundamental","pubTime":"2026-01-27 20:00","pubTimestamp":1769515201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUAL7JFC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"gpt_icon":0},{"id":"2604941401","title":"Opus Genetics Inc : Btig Initiates Coverage With Buy Rating; Target Price $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2604941401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604941401?lang=en_us&edition=fundamental","pubTime":"2026-01-20 19:00","pubTimestamp":1768906833,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nFWN3YL09S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"gpt_icon":0},{"id":"2604494194","title":"Opus Genetics initiated with a Buy at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2604494194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604494194?lang=en_us&edition=fundamental","pubTime":"2026-01-20 18:45","pubTimestamp":1768905908,"startTime":"0","endTime":"0","summary":"BTIG analyst Thomas Shrader initiated coverage of Opus Genetics (IRD) with a Buy rating and $7 price target Opus is a developmental stage biotechno...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-initiated-with-a-buy-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-initiated-with-a-buy-at-btig-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2604191641","title":"Opus Genetics Initiated at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2604191641","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604191641?lang=en_us&edition=fundamental","pubTime":"2026-01-20 18:22","pubTimestamp":1768904520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 20, 2026 05:22 ET (10:22 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2601036620","title":"Opus Genetics Inc: Expects Its Existing Cash Resources Will Fund Operations Into Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2601036620","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601036620?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:04","pubTimestamp":1767873869,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y9106:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4007","BK4139"],"gpt_icon":0},{"id":"2601536641","title":"Opus Genetics expects cash to fund operations into second half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2601536641","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601536641?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:00","pubTimestamp":1767873635,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. reported a cash and cash equivalents balance of $30.8 million as of September 30, 2025. Following a registered direct offering of equity securities, the company raised an additional $23.0 million in gross proceeds, bringing its total cash position to over $50 million. Based on current operating plans, Opus Genetics expects its existing cash resources will fund operations into the second half of 2027, not including potential proceeds from callable warrants or future milestone payments. There were no significant variations in business performance for the period reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL49dyzZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4007","NDAQ","SG9999014005.SGD","BK4585","LU2210149790.SGD","SG9999014021.USD","BK4112","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","BK4139","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014013.SGD"],"gpt_icon":0},{"id":"2600016139","title":"Independent Chairman of Opus Genetics Picks Up 9.5% More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2600016139","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600016139?lang=en_us&edition=fundamental","pubTime":"2026-01-03 20:34","pubTimestamp":1767443689,"startTime":"0","endTime":"0","summary":"Investors who take an interest in Opus Genetics, Inc. ( NASDAQ:IRD ) should definitely note that the Independent...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ird/opus-genetics/news/independent-chairman-of-opus-genetics-picks-up-95-more-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ird/opus-genetics/news/independent-chairman-of-opus-genetics-picks-up-95-more-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IRD","BK4007"],"gpt_icon":0},{"id":"2600701184","title":"Opus Genetics Director Cam Gallagher Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600701184","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600701184?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:34","pubTimestamp":1767216847,"startTime":"0","endTime":"0","summary":"Cam Gallagher, Director at Opus Genetics Inc., reported the acquisition of common shares of Opus Genetics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDLbCvm0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Opus Genetics Director Cam Gallagher Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","IRD"],"gpt_icon":0},{"id":"2592908391","title":"Opus Genetics Inc - on Dec 17, Viatris Files Supplemental Nda With FDA for Phentolamine - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2592908391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592908391?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:20","pubTimestamp":1766179246,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XP0D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1839511570.USD","VTRS","BK4007","BK4139","BK4585","IRD","LU2087621335.USD","BK4583","BK4588"],"gpt_icon":0},{"id":"2592937687","title":"Opus Genetics Grants Stock Options to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2592937687","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592937687?lang=en_us&edition=fundamental","pubTime":"2025-12-17 05:01","pubTimestamp":1765918871,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc. has granted an equity award to a new non-executive employee in the form of options to purchase 50,000 shares of the company's common stock. The options have an exercise price equal to the fair market value on the grant date and will vest over four years, with 25% vesting after one year and the remaining 75% vesting in quarterly installments thereafter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDLc7rrhY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","BK4139","IRD","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","BK4112","LU0314104364.USD","SG9999014039.USD","BK4007","BK4585","IE00B64PRP62.GBP","LU2095319765.USD","BK4588","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2590542374","title":"Foundation Fighting Blindness Retinal Degeneration Fund Sells Common Shares of Opus Genetics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590542374","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590542374?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:36","pubTimestamp":1765492589,"startTime":"0","endTime":"0","summary":"Foundation Fighting Blindness Retinal Degeneration Fund reported a disposal of common shares of Opus Genetics Inc. , according to a recent SEC Form 4 filing. The form was filed by more than one reporting person, including Foundation Fighting Blindness Retinal Degeneration Fund and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL7htR86:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Foundation Fighting Blindness Retinal Degeneration Fund Sells Common Shares of Opus Genetics Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"gpt_icon":0},{"id":"2590518414","title":"Opus Genetics CEO to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2590518414","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590518414?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:00","pubTimestamp":1765454413,"startTime":"0","endTime":"0","summary":"Opus Genetics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases, will present at the J.P. Morgan 2026 Healthcare Conference. The presentation, led by CEO George Magrath, M.D., is scheduled for Thursday, January 15, 2026, at 8:15 a.m. PT. A live and archived webcast of the presentation will be available on the company's website under the Investors section.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire  on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLWtqWr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","BK4139","IRD","SG9999014021.USD","BK4007","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014005.SGD","BK4585","NDAQ","LU0314104364.USD","BK4112","SG9999014013.SGD","BK4588","LU2095319765.USD","IE00B64PRP62.GBP"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":68,"code":"91000000","status":"200"}]}}